Isomorphic Labs Secures $5 Billion in Series C Funding to Advance AI-Driven Drug Design

Isomorphic Labs Secures $5 Billion in Series C Funding



Isomorphic Labs, a groundbreaking AI company focused on the design and development of new drugs, has officially announced a remarkable $5 billion Series C funding round. The round was co-led by prominent investors Greenoaks and Sequoia Capital, alongside contributions from Andreessen Horowitz and numerous other new stakeholders. Alphabet also maintained a significant investment, ensuring strong support from its existing investor network, which includes Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.

This fundraising effort supports Isomorphic's ambitious goals of refining its proprietary drug design engine, known as the IsoDDE, as well as expanding its pipeline of therapeutic candidates developed both internally and in partnership with other organizations. The IsoDDE integrates a suite of fundamental simulation AI models that are adaptable across various therapeutic areas and drug classes. It enables the company to explore extensive chemical spaces to design, refine, and deliver precisely constructed molecules with optimal drug-like properties.

The technology's bandwidth and precision boast predictive accuracy comparable to experimental results, allowing Isomorphic to push the boundaries of innovative drug development. Combined with proprietary algorithms that navigate and analyze complex biological systems, these models direct and replicate advancements in the company’s multimodal pipeline of therapeutic candidates, addressing some of the most challenging issues in the pharmaceutical industry.

With this significant capital influx, Isomorphic Labs is poised to propel scientific breakthroughs and enhance its AI capabilities. The firm is committed to maturing the IsoDDE while pushing deeper into unexplored biological territories to bring forth new and transformative classes of therapeutics. As part of this strategy, Isomorphic is also cultivating a partner ecosystem aimed at advancing the understanding of mechanistic disease biology.

Furthermore, the proceeds from this funding will bolster the development of a scalable, AI-oriented infrastructure for translational and clinical research, paving the way for Isomorphic's drug candidates to enter clinical trials. CEO Sir Demis Hassabis remarked, “When we founded Isomorphic, we believed that biology could be understood, modeled, and radically accelerated through AI at the most fundamental molecular level. Our drug design engine generates molecules with unprecedented precision and speed. This funding round will allow us to fast-track our foundational developments in biological modeling, deepen our systemic understanding of diseases, and advance our first therapeutic programs toward clinical studies to yield tangible results for patients.”

Max Jaderberg, President of Isomorphic Labs, shared insights on the company’s progress, stating, “Each week we achieve repeatable scientific advancements with our models. These directly lead to improved molecular profiles with the potential to become new drugs, solving some of the toughest problems in drug discovery. Our interdisciplinary teams bring together leading researchers in machine learning with top-tier drug discovery scientists who regularly work through complex biological challenges that have long stymied traditional research. We are turning our findings directly into potential life-changing medications — building on the infrastructure that we establish with this investor support for the future of bioengineering.”

Neil Mehta, founder and managing partner at Greenoaks, expressed confidence in Isomorphic's mission, stating, “The discovery and development of new drugs represent an optimization challenge of nearly infinite scale. Isomorphic fundamentally transforms this pathway by developing deep-learning systems with remarkable accuracy to foresee complex biological behaviors, systematically charting the path to new medications. We are proud to support Demis, Max, and the Isomorphic team in shaping the future of AI-driven drug research.”

Konstantine Buhler, a partner at Sequoia Capital, articulated the impact of Isomorphic's innovations, noting, “Isomorphic Labs is developing fundamental technologies for the future of medicine. It is inspiring to see how the Isomorphic team applies advanced AI to build a growing portfolio of drug candidates. Utilizing AI to enhance human health is among the most critical challenges of our generation. We are proud to co-lead this funding round and contribute to advancing scientific discoveries in medicine.”

About Isomorphic Labs


Founded in 2021, Isomorphic Labs is on a mission to revolutionize drug discovery through the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Guided by CEO Sir Demis Hassabis and President Max Jaderberg, the company has developed a world-leading AI engine for drug design that comprises foundational AI models applicable across multiple therapeutic areas and drug classes. Continually innovating in model architecture, Isomorphic Labs develops cutting-edge features to drive drug design forward. Headquartered in London, with additional offices in Cambridge, Massachusetts, and Lausanne, Switzerland, Isomorphic Labs is aggressively advancing a diverse and ambitious drug design portfolio through partnership programs and fully proprietary initiatives.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.